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Background: Long non-coding RNAs (lncRNAs) are pervasively transcribed in the genome. They have important
regulatory functions in chromatin remodeling and gene expression. Dysregulated lncRNAs have been studied in
cancers, but their role in esophageal squamous cell carcinoma (ESCC) remains largely unknown. We have conducted
lncRNA expression screening and a genome-wide analysis of lncRNA and coding gene expression on primary tumor
and adjacent normal tissue from four ESCC patients, tend to understand the functionality of lncRNAs in carcinogenesis
of esopheagus in combination with experimental and bioinformatics approach.
Methods: LncRNA array was used for coding and non-coding RNA expression. R program and Bioconductor packages
(limma and RedeR) were used for differential expression and co-expression network analysis, followed by independent
confirmation and functional studies of inferred onco-lncRNA ESCCAL-1 using quantitative real time polymerase chain
reaction, small interfering RNA-mediated knockdown, apoptosis and invasion assays in vitro.
Results: The global coding and lncRNA gene expression pattern is able to distinguish ESCC from adjacent normal
tissue. The co-expression network from differentially expressed coding and lncRNA genes in ESCC was constructed, and
the lncRNA function may be inferred from the co-expression network. LncRNA ESCCAL-1 is such an example as a
predicted novel onco-lncRNA, and it is overexpressed in 65% of an independent ESCC patient cohort (n = 26). More
over, knockdown of ESCCAL-1 expression increases esophageal cancer cell apoptosis and reduces the invasion in vitro.
Conclusion: Our study uncovered the landscape of ESCC-associated lncRNAs. The systematic analysis of coding and
lncRNAs co-expression network increases our understanding of lncRNAs in biological network. ESCCAL-1 is a novel
putative onco-lncRNA in esophageal cancer development.
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initiatomeBackground
The human genome contains many thousands of long
noncoding RNAs (lncRNAs), which are endogenous
RNA transcripts with more than 200 nucleotides, and
they lack protein coding potential [1]. LncRNAs are gen-
erally expressed at a lower level than protein-coding
genes, they display more tissue-specific and cell-specific* Correspondence: caoweiyu@hotmail.com
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demonstrated that lncRNAs participate in numerous
cellular processes ranging from embryonic stem cell
pluripotency, cell-cycle regulation, and diseases, such as
cancer [3]. An emerging theme of lncRNAs-mediated
gene regulatory network is the interaction with ribonu-
cleotprotein complexes and post-transcriptional modifi-
cation of coding genes. The regulatory mechanisms are
exemplified by X inactive specific transcript (Xist)-mediated
X chromosomal inactivation [4] and HOX transcript anti-
sense RNA (HOTAIR)-medicated HOX D cluster in Chr 2
[5]. With the advent of high-throughput microarray andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been annotated in the mammalian genome [6]. However,
only a fraction of the lncRNAs’ functions have been charac-
terized experimentally. Hence, prediction of lncRNAs’ func-
tions with multiple model systems provides guideline for
further experimental investigations [7,8].
Oesophageal cancer (EC) is the eighth most common
cancer worldwide, with an estimated 456,000 new cases
in 2012 (3.2% of all cancer), and the sixth most common
cause of death from cancer with an estimated 400,000
deaths (4.9% of the total) [9]. EC comprises of two dif-
ferent histopathological forms: esophageal adenocarcin-
oma (EAC) and esophageal squamous cell carcinoma
(ESCC). Despite the advances in contemporary treatment,
the outcome of EC remains looming. The underlying mo-
lecular mechanism of these two forms are distinct. Recent
high-throughput cancer genome sequencing revealed a
handful of common known somatic gene mutations (TP53,
CDKN2A, SMAD4, ARID1A and PIK3CA) and novel som-
atic gene mutations including chromatin modifying factors
in EAC [10], and some previously undescribed gene muta-
tions (ADAM29 and FAM135B) were detected in ESCC
[11]. While most researches on esophageal cancer still
focus on 2% of coding genes in the genome, lncRNA biol-
ogy opens the door to understand more about the cancer
initiatome which is the collective information of cellular
malignant transformation [12].
The role of lncRNAs in cancer has drawn great atten-
tion in recent years. Dysregulated lncRNAs in different
cancer suggest that lncRNAs are an enigmatic component
of the whole transcriptome, which may involve in tumori-
genesis, invasion and metastasis [13]. Detection of aber-
rant expression of lncRNAs in various tissue origin of
cancers could serve as novel biomarkers for cancer
diagnosis and prognosis. For example, the cancer-
related lncRNA, MALAT-1 (Metastasis-Associated in
Lung Adenocarcinoma Transcript 1), was identified by
subtractive hybridization during screening for early
non-small cell lung cancer with metastasis. Elevated
MALAT-1 expression was highly predictive of poor prog-
nosis and shortened survival time in early stage lung can-
cer [14]. Up-expression of HOTAIR lncRNA was found in
several solid tumors [15-19] in association with cancer
metastasis. Increased HOTAIR expression in breast cancer
is transcriptionally induced by Estradiol [20]. PCGEM1
[21] and PCAT-1 [22] are prostate cancer associated
non-coding RNA transcripts that are new components of
cell apoptosis and proliferation pathways. The studies on
lncRNAs are starting to become the center of esophageal
cancer biology in the past two years. Wu et al found a
long non-coding RNA transcript, AFAP1-AS1, highly
expressed in esophageal adenocarcinoma, the functional
experiments showed AFAP1-AS1 promotes invasion and
metastasis in esophageal cancer cells [23]. More recently,aberration lncRNA expressions in esophageal cancer
were reported, such as up-regulation of HOTAIR
[19,24-26], taurine-upregulated gene 1 (TUG1) [27],
PlncRNA1 [28], POU3f3 [29], FOXCUT [30], HNF1A-
AS1 [31], ANRIL [32] and signature identification
(lncRNAs ENST00000435885.1, XLOC_013014 and
ENST00000547963.1) [33]. However, our understanding
of lncRNAs in esophageal cancer biology is still in infancy.
In our previous study, in silico locus control analysis iden-
tified lncRNA ESCCAL-337 (chr3:171506370-171528740)
and ESCCAL-356 (chr5:1544500-1567142, reverse strand)
may modulate lipid metabolism genes contributing to
esophageal cancer development [34]. In this report, we
use more stringent bioinformatics analysis to dissect the
ESCC-related lncRNAs and unbiasedly construct the in-
teractions between lncRNAs and coding-gene expression.
From this analysis, we choose a significantly up-regulated
ESCCAL-1 lncRNA for further experimental investigation
with small interfering RNA technique, the results suggest




Primary ESCC tumors and adjacent non-neoplastic tis-
sues were obtained from four patients (all male, average
age was 66 years old) with later clinical stages who
underwent surgical treatment at Linxian Hospital on
May 2012. The informed consent was obtained from the
patients before surgery. The study protocol was ap-
proved by the Institutional Review Board for the use of
human subjects at Zhengzhou Central Hospital. All tissues
were frozen in liquid nitrogen immediately after surgical
resection. None of the patients had prior chemotherapy or
radiotherapy, nor did they have any other serious diseases.
All ESCC tissues were histopathologically diagnosed by at
least two independent senior pathologists.
Microarray hybridization
Total RNAs were extracted using Trizol reagent (Invi-
trogen, Carlsbad, CA, USA) following manufacturer’s
instruction. The quality of RNAs was measured with a
2100 Bioanalyzer (Agilent technology, USA). Input of
100ng of total RNA was used to generate Cyanine-3
labeled cRNA according to the Agilent One-Color
Microarray-Based Gene Expression Analysis Low for
Input Quick Amp Labeling kit (v6.0). Samples were
hybridized on Agilent SurePrint G3 Human GE 8x60K
Microarray (Design ID 028004). Arrays were scanned
with the Agilent DNA Microarray Scanner at a 3 μm
scan resolution and data were processed with Agilent
Feature Extraction 11.0.1.1. The microarray data discussed
in this article have been deposited in National Center
for Biotechnology Information (NCBI) Gene Expression
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accession number GSE45350 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE45350). This data was also
used in our previous study with different locus control
analysis [34].
Bioinformatic analysis
The raw intensity data was exported to GeneSpring 12.0
(Agilent Technologies, Santa Clara, CA, USA) for quantile
normalization. The normalized data containing 42544
probes were further analyzed using the R program. 139
positive control probes were removed. We then defined
the coding (“NM_”, “XM_”) and non-coding (“lincRNA”,
“NR_” and “XR_”) genes in the normalized data according
to the definition of RefSeq accession format (http://
www.ncbi.nlm.nih.gov/projects/RefSeq/key.html). The land-
scape of whole transcriptome (lncRNAs + coding RNAs),
lncRNAs only and coding RNAs only were analyzed with
gene expression dynamic inspector (GEDI) [34,35].
Differential expression
Differential expression analysis was conducted in R
environment using Limma (linear models for microarray
data) package [36]. Differentially expressed genes were
considered with P-value of 0.001 with FDR control. DE-
lncRNAs and DE-coding gene expressions are displayed
in genome view (hg19) with RCircos plot.
Co-expression analysis
Co-expression analysis was conducted in R environment
using RedeR package [37]. RedeR package has a strong
statistical pipeline for several network analysis. Here, we
have used co-expression analysis, computing a null dis-
tribution via permutation and returning the significant
correlation values. We performed 1000 permutations to
build the null distribution and used Pearson correlation.
We considered correlations with p-value less than 0.01
with FDR adjustment as significant. The hierarchical
cluster analysis used the complete method which con-
siders the distances of each individual component to
progressively computing the clusters, until find a stable
state. The final result is a dendrogram presenting hier-
archical leaves, which has been used to plot the network.
To clear the visualization, clusters ware nested using the
fourth level of dendrogram to build the nests.
Validation by quantitative real time polymerase chain
reaction (Q-PCR)
Q-PCR analysis was performed on additional 26 matched
ESCC and adjacent non-neoplastic tissues for selected
lncRNAs. The primer sequences for PCR are as follows:
HOTAIR, forward 5’-GGTAGAAAAAGCAACCACGAA
GC-3’ and reverse 5’- ACATAAACCTCTGTCTGTGAG
TGCC-3’; esophageal squamous cell carcinoma-associatedlncRNA-1 (ESSCAL-1) (chr8:76121095-76189420 reverse
strand), forward 5’-CCAGACAGCAGCAAAGCAAT-3’
and reverse 5’- GGAAGCAGCAAATGTGTCCAT-3’;
GAPDH was used as a control, forward 5’-CCGGG
AAACTGTGGCGTGATGG-3’ and reverse 5’-AGGTG
GAGGAGTGGGTGTCGCTGTT-3’. The total RNA ex-
traction with Trizol reagent (Invitrogen, Carlsbad, CA,
USA) and cDNA preparation (High capacity cDNA reverse
transcription kit, life technology, USA) were done following
manusfactures’ instruction. Q-real time PCR was per-
formed on ABI7900HT PCR machine (Applied Biosystems,
USA) using faststart universal SYBR Green Master Mix kit
(Roche, Germany). 1μl of cDNA for each sample in 10 μl
reaction. The thermocycle conditions are as follows: initial
denaturation at 94°C for 10 minutes, followed by 94°C
for 15 seconds, 60°C for 1 minute, for 40 cycles. Ct
(cycle of threshold) values were used to calculate the
relative lncRNA expression level. ΔCt = (Ct lncRNA-
CtGAPDH), while ΔΔCt = (Ct lncRNAinTumor -CtGAPDHinTumor) -
(Ct lncRNAinNormal -CtGAPDHinNormal). The fold change
of lncRNA expression in ESCC relative to normal
tissue is 2 –ΔΔCt.
Long non-coding RNA ESCCAL-1 knockdown experiment
Three small interfering RNAs were designed to target
various region of ESCCAL-1 gene expression. The se-
quences for ESCCAL-1 siRNA_1, 2, 3 are: 5’ CCGG
GAGGAGAAAGACCCAAGCACTCGAGTTTGCTTG
GGTCTTTCTCCTCTTTTTG 3’; 5’ CCGG CACATTC
ATGGTGTTGAGAAA CTCTAG TTTCTCAACACC
ATGAATGTG TTTTTG 3’; and 5’ CCGG TAGCAG
AACAACACCTGGCAA CTCGAG TTGCCAGGTGT
TGTTCTGCTA TTTTTG 3’, respectively. The negative
control siRNA sequence is: 5’-CCGGTTCTCCGAACG
TGTCACGTTTCAAGAGAACGTGACACGTTCGGA
GAATTTTTG-3’. These oligonucleotides were annealed
and subcloned into the Agel and EcoR1 sites of the
hU6-MCS-CMV-EGFP (GV115) viral vector (GeneChem,
shanghai) according to the manufacture’s instruction. The
shuttle vector and viral packaging system were cotrans-
fected into HEK293T cells to replicate competent lenti-
virus. The average titer is 1×108 TU/ml. The esophageal
cancer cell line EC9706 was used for viral infection. The
infection efficiency was greater than 80% as monitored
with GFP protein expression. After 72 h infection with
various ESCCL-1 siRNAs, the cells were harvested and
total RNA were extracted to examine ESCCAL-1 expres-
sion as described in Q-RT-PCR section.
Apoptosis and transwell assay
For apoptosis assay, the EC9706 cells were infected with
ESCCL-1 siRNA-1, which has maximum knockdown ef-
fect, or negative control siRNA. Five-day post-infection,
cells were collected and stained with an apoptotic marker,
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manual then detected with flow cytometry (FACSCalibur,
BD, USA).
For invasion assay, The EC9706 cells (1×105 cells) were
seeded into Transwell champer (corning 3422), then placed
into wells containing media with 30% fetal bovine serum,
and cultured for 24 hours, the cells migrated into mem-
brane were stained with Giemsa, measured with OD570;
meanwhile, 5x103 cells were seeded into 96 well plate, and
cell numbers were measured with MTT value (OD490),
the invasion rate = OD570/OD490.
Statistical analysis
Each condition has three replicates, data present with mean
and standard deviation. T-test was used for p value calcula-
tion. Significant difference is considered with p < 0.05.
Results and discussion
The landscape of ESCC transcriptome
Gene expression profiles of ESCC predominantly fo-
cused on mRNAs [38-40] and microRNAs [41,42] in the
past years. These transcripts only represent small pro-
portion of whole transcriptome in esophageal cancer
genome. LncRNAs are emerging as a novel class of
noncoding RNAs that are pervasively transcribed in the
genome [1], their expression profiling in ESCC has not
been well investigated systematically. In our study, the
genome-wide transcriptome including 7,419 intergenic
lncRNAs along with 27,958 mRNAs were examined in
ESCC and adjacent normal tissue. The expression of
whole transcriptome (lncRNAs and mRNAs) on the micro-
array is able to distinguish ESCC from normal tissue with
unsupervised hierarchical clustering (Figure 1A). Next, we
examined the whole transcriptomic pattern from each
groups using gene expression dynamics inspector (GEDI),
which accentuates a novel holistic perspective [35]. The
mosaic pattern of whole transcriptome derived from nor-
mal tissues is different from that of ESCC. We further mea-
sured the holistic expression profiling of either lncRNAs or
coding RNAs from each sample, again the overall changes
from normal to cancer state were also seen in the compo-
nents of whole transcriptome of ESCC. From the view of
systems biology, neither lncRNAs nor mRNA expression
pattern could represent the whole transcriptome of ESCC,
the interaction between the components (lncRNAs and
coding RNAs) may be reshaping the landscape of the whole
transcriptome during ESCC development.
Differential expression of lncRNAs and coding RNAs in ESCC
In order to find what coding and non-coding RNAs con-
tribute to the cellular malignant transformation, we used
liner model for microarray analysis (limma) to exam the
expression level of RNA transcripts remarkably changed
in ESCC relative to normal tissue. Limma model hasmore statistical power to detect differentially expressed
genes, and also produces relative more reliable gene
ranking with fewer false discoveries. From this analysis,
a total of 128 genes including coding and non-coding
(lncRNAs) were identified with highly significant change
(p < 0.001, Bonferroni correction) (Additional file 1:
Table S1). Among them, 95 are coding genes, 33 are
noncoding genes. Most of these significantly differen-
tially expressed RNA transcripts were downregulated in
ESCC (Figure 1B). A subset of these differential gene
expressions are consistent with the literature, such as
aberrant coding gene expression of ARSF, DMRTA1,
MAGEA1, ECM1, HIPK2, and PIK3C2G were detected
in other studies in esophageal cancer [43,44]. Non-
coding gene ESCCAL-1 has been validated in extra three
ESCC samples as shown in our previous study [34].
Construction of co-expression network between coding
and lncRNA genes in ESCC
The function of specific coding genes [38-40] and micro-
RNAs [41,42] are well studied in ESCC, in contrast,
lncRNA functions in ESCC remain largely unknown.
The compelling evidence show that biological networks
contain modules of genes or proteins that may function
in the same pathway, genes or proteins inside a module
can be co-regulated, they are often represented by one
single node in the network [7]. Therefore, Computa-
tional construction of coding and non-coding gene co-
expression network with different algorithms could infer
the lncRNA potential biological functions [7,8]. We used
a well-developed computational algorithm, RedeR [37],
to construct the co-expression network on the 128 dif-
ferentially expressed RNA transcripts (coding RNAs and
lncRNAs). The distribution of association between coding
genes and lncRNA gene is calculated (pearson correlation,
p < 0.01) and displayed in Figure 2A. The significant corre-
lated genes were selected for the construction of co-
expression network. We dissected eight modules, which
comprise of various nodes in the network. Interestingly,
most modules include down-regulated genes, only one
module is the connection of up-regulated genes (Figure 2B,
for the coding RNA annotation, please see Additional file 2:
Figure S1.). A grouped genes in each nodes may execute
same or similar functions, which is biological basis for
inference of unknown gene functions including lncRNAs.
Prediction of lncRNA functions based on co-expression
network
Since lncRNAs’ functions are largely unknown, prediction
of their putative functions now rely on the co-expression
network [7,8]. From the co-expression network based on
128 differential expression of lncRNAs and coding genes,
we focused on one of the up-regulated nodes in meddle of
Figure 2B. This selected module is composed of two




Figure 1 Transcriptomic landscape of esophageal squamous cell carcinoma (ESCC). (A) Unsupervised hierarchical clustering analysis of
genome-wide RNA transcripts in ESCC and adjacent normal tissue using a microarray with 7,419 long noncoding RNAs (lncRNAs) and 27,958 coding
RNAs. A self-organizing map (SOM) of either whole transcriptome (both lncRNAs and mRNAs) or lncRNAs or mRNA was produced from each group
samples using gene expression dynamic inspector (GEDI). Mosaic patterns are pseudo-colored SOMs to show integrated biological entity in
each sample. The color gradient from red to blue color indicates the expression level from high to low. (B) Liner models for microarray data
analysis (limma) identified differentially expressed lncRNAs (DE-lncRNAs) and coding genes (DE-coding gene) in ESCC relative to normal tissue.
FDR < =0.01, P <0.001. DE-lncRNAs and DE-coding gene expressions are displayed in genome view (hg19) with RCircos plot. In each circle view,
blue line: downregulation, red line: upregulation.
Hao et al. BMC Cancer  (2015) 15:168 Page 5 of 10lncRNAs: one is HoxA11-AS1 (HoxA11 antisense
RNA), another is ESCCAL-1(Esophageal Squamous
Cell Carcinoma Associated LncRNA-1). The module also
includes six protein-coding genes, they are COL10A1,
MMP11, LEPREL4, FNDC1, MAGEA1, INHBA. HoxA11-
AS1 is evolutionary conservation and tissue-specificexpression [45], It was proposed that HOXA11 antisense
represses HOXA11 expression by competing for tran-
scription of the common gene, rather than by sense/
antisense interaction [46]. The link of HOXA11-AS1
to cancer is unknown; it is the interest for future study.
Because we have confirmed elevated expression of
Figure 2 Co-expression network of esophageal squamous cell carcinoma. (A) Pearson correlation of DE-lncRNAs and DE-coding genes.
(B) Co-expression of esophageal squamous cell carcinoma has been performed after differential expression analysis involving tumor (n = 4)
against normal tissue (n = 4). Resulting clusters were nested to clear the visualization. The nests were numbered from Nt 1 to Nt7. Link width
represents number of interactions among clusters. Red nodes represent increased transcription comparing to control and blue nodes represent decreased
transcription comparing to control. Circles represents coding RNA and squares represents long non-coding RNA. Dashed lines enclosing clusters
of co-expressed genes. Long non-coding RNAs are numbered and the respective annotation is present on the bottom of the figure. For the coding
RNA annotation, please see Additional file 2: Figure S1.
Hao et al. BMC Cancer  (2015) 15:168 Page 6 of 10ESCCAL-1 in independent three samples [34], and
ESCCAL-1 is the focus of this study. LncRNA ESCCAL-1
is also named RP11-697M17.1 from GENCODE transcriptannotation ENST00000504531.2 or CASC9 (cancer sus-
ceptibility candidate 9) from Refseq annotation (Figure 3A).
The transcriptional regulation of ESCCAL-1/CASC9 has
BA
Figure 3 The lncRNA ESCCAL-1 expression in ESCC. (A) UCSC genome browser view of ESCCAL-1 (chr8:76139826-76139767). This lncRNA is
also known as RP11-697M17.1 from GENCODE transcript annotation or ENST00000504531.2 or CASC9 (cancer susceptibility candidate 9) from
Refseq annotation. The transcriptional regulation of ESCCAL-1/CASC9 has been evaluated by ENCODE (detailed seen Additional file 3: Figure S2).
(B) ESCCAL-1 expression was further examined in independent 26 pair-matched normal and ESCC samples, its expression was significantly
higher in 17 out of 26 (65%) ESCC samples relative to normal tissue. LncRNA HOTAIR, a known oncogenic lncRNA was also measured as a
positive control.
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file 3: Figure S2). For coding genes in this selected node,
MMP11 [47], FNDC1(also known as MEL4B3) [48],
MAGEA1 [49], INHBA [50] are experimentally demon-
strated positive associated with cancers. According to
this prediction, we reasoned the “oncogenic” role of
ESCCAL-1 in ESCC development. Therefore, we ex-
amined ESCCAL-1 expression in 26 paired wise inde-
pendent cohort samples using quantitative RT-PCR, itturns out that ESCCAL-1 is highly expressed in 65% of
ESCC samples relative to adjacent normal tissues, its
higher expression frequency in ESCC is compatible with
onco-lncRNA HOTAIR expression in ESCC [19].
Reverse the phenotype of esophageal cancer cells by
reducing ESCCAL-1 expression
We want to know how esophageal cancer cell behavior
changes if knocking down the expression of ESCCAL-1
Hao et al. BMC Cancer  (2015) 15:168 Page 8 of 10lncRNA, we therefore designed three small interfering
RNAs targeting various region of ESCCAL-1 sequencing.
The esophageal cancer cell line EC9706 with higher
ESCCAL-1 expression (data not shown) was infected
with lentivirus containing either control or ESCCAL-1
siRNA, after 72 h infection, all three ESCCAL-1 siR-
NAs can remarkably reduce ESCCAL-1 expression
with maximal inhibition of 65% (Figure 4A). We used
ESCCAL-1 siRNA-1 for further biological experiments.
The apoptotic cells increased and invasive capacity
decreased significantly in cell infected with ESCCAL-1
siRNA-1 compared to control cells (p < 0.05). This
experimental data suggest that ESCCL-1 may act to-
gether with abovementioned coding genes to inhibit
cell death program and facilitate the invasion and me-
tastasis. As we are revising our manuscript, at least 11
lncRNAs were reported to be upregulated in ESCC
relative to adjacent normal tissue, overexpression of
these lncRNAs are associated poor prognosis and me-
tastasis of ESCC [19,23,27-33]. Core signaling path-
ways may be disrupted by these aberrant lncRNA
expressions, such as WNT pathway is activated by
HOTAIR over expression [25], TGFbeta1 pathway is
inhibited by ANRIL [32]. Our study here provides an
additional ESCC-associated lncRNA as a biomarker forFigure 4 Knockdown of ESCCAL-1 expression increases apoptosis
significantly reduced by three individual small interfering RNAs with maximu
ESCCAL-1 siRNA_1. (B) Apoptosis assay showed EC9706 cells infected with
(C) Transwell invasion assay displayed reduced cell migration of ESCCAL-1
* P < 0.05.ESCC diagnosis and prognosis. The detail mechanisms
remain to be investigated.Conclusion
We performed a genome-wide survey of the expression
of lncRNAs and coding RNAs from primary ESCC tis-
sue and adjacent normal tissue in four individuals. The
overall transcriptomic landscape is able to distinguish
malignant from normal tissue in each patients. Inter-
action between lncRNAs and coding RNAs may re-
shape the landscape of the whole transcriptome during
ESCC development. The stringent liner model analysis
identified 128 significantly differentially expressed cod-
ing and non-coding RNA transcripts in ESCC relative
to normal tissue. More strikingly, the co-expression
network constructed the potential functional modules
and sub-networks linking lncNRAs with coding genes.
From one of the sub-networks, we inferred ESCCAL-1
putative oncogenic role in ESCC and verified its up-
regulation in an independently cohort. The knockdown
of ESCCAL-1 expression increases apoptosis and
decrease invasion in intro. This proof of principle
study provides a systematic strategy to study lncRNA
functionality.and reduces invasion in vitro. (A) ESCCAL-1 expression was
m ~65% reduction in EC9706 esophageal cancer cells infected with
ESCCAL-1_siRNA_1 increased as twice apoptotic cells as control cells.
_siRNA_1 infected EC9706 cells in comparison with control cells.
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Additional file 1: Table S1. Differential expression of lncRNAs and
mRNAs in esophageal squamous cell carcinoma relative to adjacent
normal tissue (p < 0.001, FDR < 0.01).
Additional file 2: Figure S1. Co-expression of esophageal squamous
cell carcinoma has been performed after differential expression analysis
involving tumor (n=4) against normal tissue biopsies (n=4). Seven
subnetworks were determined from the differentially expressed coding
and lncRNA genes. Red nodes represent increased transcription comparing
to control and blue nodes represent decreased transcription comparing to
control. Circles represents coding RNA and squares represents long chain
non-coding RNA. Long non-coding RNAs are numbered and the respective
annotation is present on the bottom of the figure.
Additional file 3: Figure S2. LncRNA ESCCAL-1 (chr8:76139826-76139767)
was displayed in UCSC genome browser with transcriptional and epigenetic
modification detected by ENCODE analysis.
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